Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community

作者：B. Ultsch, Oliver Damm, Philippe Beutels, Joke Bilcke, Bernd Brüggenjürgen, Andreas Gerber‐Grote, Wolfgang Greiner, Germaine Hanquet, Raymond C. W. Hutubessy, Mark Jit, Mirjam J. Knol, Rüdiger von Kries, Alexander Kuhlmann, Daniel Lévy-Bruhl, Matthias Perleth, Maarten Jacobus Postma, Heini Salo, Uwe Siebert, Jürgen Wasem, Ole Wichmann · 发表于：PharmacoEconomics · 年份：2015 · DOI：10.1007/s40273-015-0335-2 · 被引用次数：119 · 研究领域：Health Systems, Economic Evaluations, Quality of Life、Vaccine Coverage and Hesitancy、Diphtheria, Corynebacterium, and Tetanus

BACKGROUND: Incremental cost-effectiveness and cost-utility analyses [health economic evaluations (HEEs)] of vaccines are routinely considered in decision making on immunization in various industrialized countries. While guidelines advocating more standardization of such HEEs (mainly for curative drugs) exist, several immunization-specific aspects (e.g. indirect effects or discounting approach) are still a subject of debate within the scientific community. OBJECTIVE: The objective of this study was to develop a consensus framework for HEEs of vaccines to support the development of national guidelines in Europe. METHODS: A systematic literature review was conducted to identify prevailing issues related to HEEs of vaccines. Furthermore, European experts in the field of health economics and immunization decision making were nominated and asked to select relevant aspects for discussion. Based on this, a workshop was held with these experts. Aspects on 'mathematical modelling', 'health economics' and 'decision making' were debated in group-work sessions (GWS) to formulate recommendations and/or--if applicable--to state 'pros' and 'contras'. RESULTS: A total of 13 different aspects were identified for modelling and HEE: model selection, time horizon of models, natural disease history, measures of vaccine-induced protection, duration of vaccine-induced protection, indirect effects apart from herd protection, target population, model calibration and validation, handling uncertainty, ...